Pharmafocus Home
    
Keyword Search
Go News Archive Features Events Appointments Jobs Contact Us About Us
Latest Features ( May )
Should I stay or should I go?
There are no easy answers when it comes to timing a job move, says Tim Ewbank, but you can make yourself a more attractive candidate for that next job.(more)
Regional research still hampered by cross-border differences
In the age of the Euro-trial, patients are not well served by processes that add unnecessary delays to the development of new medicines, says Les Rose(more)
A sea of paperwork or business as usual?
Steven Gray looks ahead to the soon-to-be finalised 2008 ABPI Code of Practice and how it will affect everyday practice in the UK industry(more)
Pharmafocus.comNews Headlines Register for News Alert
News for April 2008
Previous Months: April 2008 |  March 2008 |  February 2008 |  January 2008 |  December 2007 |  November 2007 |  October 2007 |  September 2007 |  August 2007 |  July 2007 |  June 2007 |  May 2007 |  April 2007 |  March 2007 |  February 2007 |  January 2007 |  December 2006 |  November 2006 |  October 2006 |  September 2006 |  August 2006 |  July 2006 |  June 2006 |  May 2006 |  April 2006 |  March 2006 |  February 2006 |  January 2006 |  December 2005 |  November 2005 |  October 2005 |  September 2005 |  August 2005 |  July 2005 |  June 2005 |  May 2005 |  April 2005 |  March 2005 |  February 2005 |  January 2005 |  December 2004 |  November 2004 |  October 2004 |  September 2004 |  August 2004 |  July 2004 |  June 2004 |  May 2004 |  April 2004 |  March 2004 |  February 2004 |  January 2004 |  December 2003 |  November 2003 |  October 2003 |  September 2003 |  August 2003 |  July 2003 |  June 2003 |  May 2003 |  April 2003 |  March 2003 |  February 2003 |  January 2003 |  December 2002 |  November 2002 | 

  What is RSS?

Latest news from Datamonitor
Product roundup in smallpox, depression and sepsis..(more)

 Roche's new RA treatment gains first approval
First-in-class Actemra will challenge TNFs..(more)

 Tamiflu takes the shine off Roche results
Weak dollar also undermines figures..(more)

 Lipitor loses out on Alzheimer's lifeline
Trial results scotch Pfizer's plans for a lucrative licence extension..(more)

 Polyclinics 'threaten' traditional surgeries
Conservatives attack government health reform plans..(more)

 Vaccination drive halts meningitis deaths
Government heralds success of national immunisation programme..(more)

 Vaccines 'Golden Era' under threat
Study warns against government spending squeezes..(more)

 Latest news from Datamonitor
Novartis acquires ophthalmology specialist Alcon..(more)

 United Drug expands with two acquisitions
Firm broadens reach into events and training..(more)

 Shire plans tax move to Ireland
Company HQ remains in UK and no job losses planned..(more)

 NHS accountability debate 'lacks clarity'
King's Fund says it is not even clear whether people want more control over PCTs..(more)

 AZ settles with generic challenger to Nexium
Ranbaxy wins right to sell generic version of ulcer drug from 2014..(more)

 Roche to buy Piramed
UK biotech snapped up for $160 million..(more)

 Takeda buys up biotech Millennium
Acquires US marketing rights to cancer drug Velcade..(more)

 NHS poll shows shortfall in care and hand washing
Less than two-thirds of staff always have access to the right equipment..(more)

 Boehringer Ingelheim outpaces market
Respiratory treatment Spiriva drove company growth in 2007..(more)

 Merck obesity drug to continue at low dose
Studies to continue on 2mg dose..(more)

 Major leap in statin prescribing predicted
Health screening plans could double prescriptions, says Heart Tsar..(more)

 Role of pharmacists to be extended
Proposals include taking on some GP duties..(more)

 Study confers protective benefits on Micardis
Boehringer Ingelheim's hypertension treatment comes out on top of Tritace..(more)

 Trial fails to enhance Inegy's prospects
Schering-Plough and Merck's cholesterol combination stumbles..(more)

 Latest news from Datamonitor
The impact of the US presidential race on healthcare IT..(more)

 UCB's Cimzia fails to appeal to European regulators
CHMP issues negative opinion for Crohn's disease drug..(more)

 Make Alzheimer's a top research priority, says public
ABPI survey shows disease as third most important area for pharma..(more)

Are you a Pharmafocus subscriber?

Subscribe Now 

Visit our sister sites: 

InPharm.com 

Pharmafile.com 

Pharmafocus.com © 2006 Pharmafile Ltd.